Daidzein (Isoflavone · Phytoestrogenic · Cardiovascular)

Compound	Daidzein
Chemical class	Polyphenol — Isoflavone (7,4′-Dihydroxyisoflavone)
CAS	486-66-8
Primary source	Glycine max (soybean), Pueraria lobata (kudzu root)
Key applications	Phytoestrogenic, cardiovascular, equol-dependent benefits
Claim strength	Moderate
Typical form	Daidzein 98% isolate; soy isoflavones extract
Buy from Herbuno	Daidzein Powder → Daidzein 98% Powder (Soy) | High-Purity Isolate | Glycine max →

Name origin: From Daidzu — the Japanese name for soybean (Glycine max). Daidzein is the second major soy isoflavone after genistein, present at approximately 40% of total soy isoflavone content. Traditional use: Shares the broad traditional use context of soy-based fermented foods across East Asia. Kudzu root (Ge Gen in TCM), a particularly rich daidzein source, has been used in Chinese medicine for alcohol dependence, cardiovascular complaints, and fever. Research trajectory: Daidzein’s clinical significance depends heavily on equol-producer status — approximately 30–50% of Western populations and up to 60% of Asian populations harbour the gut microbiota capable of converting daidzein to equol, a more potent phytoestrogen. Daidzein benefits are therefore population-variable. Commercial source: Daidzein is commercially available as a high-purity isolate (98% HPLC) and as a standardised daidzein powder from soy or Pueraria extraction. See sourcing options below.

---

Evidence for Daidzein Applications

Phytoestrogenic and menopausal support: Daidzein is an ERα/ERβ agonist with preference for ERβ. Clinical trials show modest hot flush reduction with daidzein-containing soy isoflavone preparations; effect is stronger in equol producers. As a standalone compound, daidzein’s estrogenic potency is approximately 3-fold lower than genistein. Claim strength: Moderate (effect size equol-dependent).

Cardiovascular and lipid modulation: Daidzein contributes to soy isoflavone cardiovascular benefits (LDL reduction, endothelial function improvement). Kudzu root isoflavone preparations (rich in daidzein and puerarin) have demonstrated blood pressure-lowering effects in small human trials. Claim strength: Moderate.

Alcohol craving reduction (kudzu context): Kudzu root extract rich in daidzein and puerarin has been studied in RCTs for reduction of alcohol consumption. The mechanism involves altered alcohol pharmacokinetics. Daidzein is considered a contributing active alongside puerarin. Claim strength: Moderate.

---

Dosage & Formulator Specification

Typical clinical dose as part of soy isoflavone complex: 40–80 mg/day daidzein equivalent (alongside equivalent genistein). As isolated daidzein 98%: 20–60 mg/day based on pharmacokinetic and mechanistic extrapolation. For equol-focused formulations, consider co-supplementing with probiotic strains (Lactobacillus spp.) documented to support equol conversion in non-producers.

Herbuno Daidzein 98% allows precise aglycone dosing. For natural-ratio isoflavone formulations, Soy Isoflavones 80% delivers genistein + daidzein + glycitein at characteristic soy ratios. Specify aglycone versus glycoside (daidzin) in product documentation — these have different bioavailability profiles.

Daidzein aglycone has low aqueous solubility (~0.02 mg/mL); similar delivery considerations to genistein apply. More heat-stable than genistein; compatible with standard tablet compression and encapsulation. Stable at pH 4–8; avoid strongly alkaline processing.

---

Frequently Asked Questions — Daidzein

What is equol and why does it matter for daidzein supplementation?
Equol is a more potent phytoestrogen produced by gut microbial conversion of daidzein. It has higher ERβ affinity than daidzein and better bioavailability. Equol-producer status (determined by gut microbiome composition) explains much of the inter-individual variability in soy isoflavone clinical trial outcomes. Formulators targeting menopausal or hormonal applications should consider including equol-producer probiotic support or pre-formed equol (if available) for consistent outcomes.

Is daidzein safer than genistein for hormone-sensitive conditions?
Daidzein has lower ERα agonism than genistein, suggesting a marginally different safety profile for hormone-sensitive conditions. However, both undergo in vivo conversion and share broad pharmacological activity. The same precautionary advisory language applies to both in the context of hormone-sensitive cancer history.

Does kudzu root provide a meaningful daidzein dose?
Yes. Kudzu root (Pueraria lobata) is one of the richest daidzein sources in nature, with roots containing 1–4% total isoflavones (primarily puerarin, daidzin/daidzein). A 500 mg dose of kudzu extract at 2% isoflavones delivers ~10 mg daidzein equivalent — below the clinical cardiovascular dose but relevant for combination formulations. Standardised kudzu isoflavone extracts (40% isoflavones) provide more consistent daidzein delivery.

Should daidzein or genistein be prioritised for a menopausal supplement?
Clinical evidence is stronger for genistein specifically in bone density and hot flush management. Daidzein’s benefit is more equol-dependent and population-variable. A combination of both at characteristic soy ratios (genistein:daidzein approximately 1.5:1) delivered via a standardised soy isoflavones extract is the most clinically defensible approach for general formulation.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery